Welcome to our dedicated page for Avanos Medical SEC filings (Ticker: AVNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From post-surgical cold-compression pumps to neonatal feeding tubes, Avanos Medical鈥檚 product line touches some of healthcare鈥檚 most sensitive moments. Investors digging into how the company manages regulatory risk, R&D spending, or global recall exposure know the answers live inside its SEC disclosures鈥攜et those files can exceed 300 pages of technical detail.
Stock Titan鈥檚 AI engine turns every Avanos Medical quarterly earnings report 10-Q filing and annual report 10-K into plain-language highlights. Need Avanos Medical insider trading Form 4 transactions before the market opens? Our real-time feed surfaces Avanos Medical Form 4 insider transactions real-time and flags patterns in executive stock transactions Form 4. Curious about supply-chain updates or FDA clearances? We tag each Avanos Medical 8-K material events explained so you see the headline without reading footnotes. Even the dense Avanos Medical proxy statement executive compensation is broken down into concise tables.
Here鈥檚 how specialists, portfolio managers, and compliance teams use the page:
- Compare non-opioid therapy revenue across periods with Avanos Medical earnings report filing analysis.
- Set alerts for understanding Avanos Medical SEC documents with AI to spot margin-moving disclosures.
- Download red-lined versions of Avanos Medical SEC filings explained simply for faster peer review.
Every document鈥�10-K, 10-Q, 8-K, S-8, Section 16 forms鈥攊s captured seconds after EDGAR posts, then summarized by our natural-language model. Historical search lets you trace clinical-trial milestones back through years of Avanos Medical annual report 10-K simplified narratives. Whether you follow digestive-health devices, pain-management trends, or simply want compliance-ready data, Stock Titan delivers the entire picture in one place, saving hours per filing and letting you focus on the investment decision itself.
On 1 Aug 2025, Charter Communications, Inc. (CHTR) filed a Form 4 reporting the routine equity compensation of its President-Product & Technology, Richard J. DiGeronimo.
- Stock options: 8,065 Class A shares at an exercise price of $267.61. Granted under the 2019 Stock Incentive Plan, they vest 100 % on 1 Aug 2028 and expire on 1 Aug 2035.
- Restricted Stock Units: 327 units, also vesting 100 % on 1 Aug 2028; price and expiration are not applicable.
No shares were sold or disposed of. Following the grants, the executive鈥檚 direct beneficial holdings now include 8,065 options and 327 RSUs. The transaction is classified with code 鈥淎,鈥� indicating an acquisition from the issuer, and represents standard incentive alignment with long-term shareholder value. No immediate earnings or cash-flow effects are disclosed in the filing.
Avanos Medical (AVNS) has filed an 8-K dated 5-Aug-25 that covers earnings disclosure, management changes and a product-line divestiture.
Item 2.02: The company furnished (not filed) a press release with results for Q2-25 and 1H-25 (Ex. 99.1); specific revenue, EPS and guidance figures are not included in this report.
Item 5.02 鈥� Leadership moves: Effective 1-Aug-25, CEO David Pacitti joined the Board, filling one vacancy. Scott Galovan (46), previously SVP-Strategy & Corp. Dev., was promoted to Senior VP & Chief Financial Officer. His package includes a $460k base salary, 70 % bonus target, a 2026 LTIP grant targeted at $1.6 m and an immediate $0.5 m time-based RSU award vesting 30 %/30 %/40 % over three years. Interim CFO Jason Pickett moves to Vice President, Corporate Finance & Treasurer.
Item 7.01 鈥� Strategic action: On 31-Jul-25 Avanos announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, LLC (Ex. 99.2). No purchase price or financial impact was disclosed in the filing.
Investors should review the attached exhibits for quantitative performance data and divestiture terms, as neither is detailed within the body of the 8-K.
On 06/30/2025, The Vanguard Group filed Amendment No. 10 to Schedule 13G reporting its ownership of Chemours Company (CC) common stock.
- Shares beneficially owned: 17,663,980
- Ownership percentage: 11.8 % of outstanding shares
- Voting power: 0 sole; 181,238 shared
- Dispositive power: 17,324,381 sole; 339,599 shared
Vanguard qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E). The firm states the position is held in the ordinary course of business and not to influence control. Clients of Vanguard retain rights to dividends and sale proceeds.
Crossing the 10 % threshold makes Vanguard a significant institutional holder, potentially enhancing liquidity and investor confidence, although its near-zero sole voting power limits direct governance influence.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
What does Avanos Medical do?
What are the core business areas of Avanos Medical?
How does Avanos Medical maintain its competitive edge in the industry?
What technologies or therapies is Avanos Medical known for?
In which markets does Avanos Medical operate?
How does Avanos Medical address patient safety and recovery?
What is the significance of the company鈥檚 transformation process?
How do Avanos Medical's products contribute to reducing opioid usage?
